Snehal Bhatt helps review EMPACT-MI and ULTIMATE-DAPT in Part 2 of the 2-part ACC 2024 rapid reaction episode series.

Snehal Bhatt reviews two of the most practice-changing research studies from ACC 2024, EMPACT-MI and ULTIMATE-DAPT, in Part 2 of the 2-part rapid reaction episode series.

The episode starts off with EMPACT-MI, published in NEJM, researching the use of empagliflozin to reduce HF-related hospitalizations and mortality post-MI. Is this another “me too” SGLT2 study? What is the effect of no central adjudication? Why are these safety findings so important? EMPACT-MI v. DAPA-MI & PARADISE-MI? Is this a normal % of STEMI patients?

Then we highlight the ULTIMATE-DAPT trial, published in Lancet. Is this the first placebo-controlled DAPT trial? What do the guidelines recommend? How does the trial geography influence generalizability? Barriers with ticagrelor-based SAPT? How to apply these findings and so much more.

Listen to Part I now